Blue Plans will now have an additional home delivery option that they can choose to offer their members.
Prime Therapeutics has launched MedsYourWay to provide members of participating Blue Plans a new home delivery option using Amazon Pharmacy. This new home delivery option with Amazon Pharmacy includes simplified sign-up, real-time medication price displays, as well as an integrated prescription discount card administered by Inside Rx. Covered purchases with the MedsYourWay prescription discount card accrue toward a member’s out of pocket maximums and deductibles.
Inside Rx, which is owned by Express Scripts, provides discounts on both brand and generic medications.
“MedsYourWay will challenge the traditional thinking in the PBM industry,” Jarrod Henshaw, senior vice president, chief innovation and supply chain officer for Prime Therapeutics, said in a statement.
Over the coming months, Prime Therapeutics will launch additional services under the MedsYourWay offering.
Amazon acquired PillPack in September 2018, for about $753 million. PillPack provides consumers with their medications in daily packages. In the acquisition, Amazon gained access to PharmacyOS, a software platform created by PillPack to help manage customer’s medications, coordinate refills and renewals.
In November 2020, the company launched Amazon Pharmacy to provide consumers with a way to manage and order prescriptions. In addition, Amazon Prime members without insurance have access to generics at 80% discount and branded therapies at a 40% discount.
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More